About Hidradenitis Suppurativa

​

Hidradenitis suppurativa (HS), also known as acne inversa or Verneuil's disease, is a chronic, recurrent, inflammatory skin disorder of the terminal hair follicles within apocrine gland-bearing regions of the body. Though once misclassified as a primary disorder of the sweat glands, contemporary understanding situates HS as a follicular occlusion disease with a dominant immunologic component. It is among the most painful and life-disrupting dermatologic conditions, frequently underdiagnosed or misattributed to recurrent boils, folliculitis, or poor hygiene for years before accurate identification.

Clinically, HS presents as deep-seated, painful inflammatory nodules, abscesses, draining sinus tracts, and rope-like hypertrophic or atrophic scars. Lesions characteristically arise in intertriginous areas — the axillae, inguinal folds, genital and perianal regions, inframammary skin, buttocks, and inner thighs — where friction, occlusion, and apocrine density converge. Severity is most commonly graded by the Hurley staging system: Stage I denotes isolated abscesses without sinus tracts or scarring; Stage II involves recurrent abscesses with limited sinus tract formation and scarring separated by normal skin; and Stage III is characterized by diffuse involvement with interconnected tracts and extensive scarring across an anatomic region. The disease typically emerges after puberty, follows a relapsing-remitting course, and disproportionately affects women, individuals with skin of color, and those with metabolic comorbidities. Its impact extends well beyond the skin, with documented associations to depression, anxiety, sexual dysfunction, and substantial reductions in quality of life.

​

Causes

​

The pathogenesis of HS is multifactorial and incompletely understood, but converges on three interrelated mechanisms:

The first is follicular occlusion, considered the primary initiating event. Hyperkeratosis and infundibular plugging of the terminal hair follicle lead to follicular rupture, spilling keratin, sebum, and bacterial contents into the surrounding dermis and triggering a profound inflammatory cascade. The second is immune dysregulation, with overactivation of innate and adaptive immunity producing elevated levels of TNF-α, IL-1β, IL-17, and IL-23 — cytokines that sustain chronic inflammation, granuloma formation, and tissue remodeling into the characteristic sinus tracts and fistulas. The third is microbial dysbiosis: while HS is not a primary infectious disease, secondary bacterial colonization with anaerobes, streptococci, and staphylococcal species — often within biofilms — perpetuates inflammation and contributes to malodor and drainage.

Secondary contributing factors include genetic predisposition, with roughly one-third of patients reporting a family history and a subset of familial cases linked to loss-of-function mutations in the γ-secretase complex genes (NCSTN, PSEN1, PSENEN). Hormonal influences are evident in the post-pubertal onset, premenstrual flares, and androgen sensitivity observed in many patients. Modifiable risk factors carry particular weight: cigarette smoking and obesity are the two most strongly associated lifestyle factors, each independently worsening disease severity and treatment response. Mechanical friction, occlusive clothing, excessive sweating, and shaving in affected areas can precipitate lesions. HS is also closely linked to systemic comorbidities including metabolic syndrome, type 2 diabetes, inflammatory bowel disease, spondyloarthropathies, and polycystic ovary syndrome, reflecting its nature as a systemic inflammatory disorder rather than a purely cutaneous one.

​

Treatment

​

Effective HS management is multimodal, stage-directed, and best delivered through a long-term therapeutic partnership between patient and clinician. Therapy spans topical, systemic, procedural, and lifestyle domains, with early intervention strongly associated with better disease trajectory.

Topical therapies are appropriate for mild (Hurley I) disease and as adjuncts at all stages. Topical clindamycin is the most studied agent and reduces superficial pustular lesions; antiseptic washes such as chlorhexidine, benzoyl peroxide, and dilute sodium hypochlorite help reduce bacterial burden and biofilm. Resorcinol 15% has demonstrated benefit in reducing painful nodules when applied to early lesions. Topical therapies alone, however, are rarely sufficient beyond the earliest stages.

Systemic antibiotics are used for their anti-inflammatory as well as antimicrobial effects. Tetracycline-class agents (doxycycline, minocycline) are commonly first-line for moderate disease. For more severe or refractory cases, the combination of oral clindamycin and rifampin for 10–12 weeks has well-established evidence. Triple therapy with rifampin, moxifloxacin, and metronidazole, or intravenous ertapenem, may be employed in selected resistant cases under specialist supervision. Hormonal therapies — including combined oral contraceptives, spironolactone, and finasteride — are valuable in appropriate patients, particularly women with cyclic flares.

Biologic therapy has transformed care for moderate to severe HS. Adalimumab (anti-TNF-α) was the first biologic approved for HS and remains a cornerstone of treatment. Secukinumab (anti-IL-17A) and bimekizumab (anti-IL-17A/F) have since received approvals based on robust trial data, offering important alternatives for patients who do not respond adequately to anti-TNF therapy. Additional agents targeting IL-1, IL-23, and JAK pathways are under active investigation and in clinical use off-label for refractory disease. Retinoids such as acitretin may benefit a subset of patients, while metformin has shown adjunctive value, particularly in those with metabolic comorbidities.

Procedural and surgical interventions remain essential. Intralesional corticosteroid injections rapidly reduce inflammation in acute nodules. Deroofing — the unroofing and curettage of sinus tracts — is a tissue-sparing technique well suited to recurrent, fixed lesions. Wide local excision of severely affected regions can achieve durable control of Hurley III disease, and laser-based modalities (Nd:YAG, CO2, intense pulsed light) provide options for hair-follicle reduction and lesion clearance. Adjunctive supports include diligent pain management, psychological care, and wound care education for draining lesions.

​

Solution

​

A durable solution to HS is not a single therapy but a sustained, individualized strategy built on three principles: early and adequate inflammation control, modification of mechanical and metabolic drivers, and management of the disease as a chronic systemic condition rather than a series of isolated flares.

Inflammation control begins with prompt recognition and treatment escalation appropriate to disease severity, avoiding the common pitfall of cycling through repeated short antibiotic courses when biologic or surgical intervention is warranted. Maintenance therapy — whether topical antiseptics, ongoing biologic dosing, or proactive lesion-directed procedures — is central to preventing the progression from reversible inflammation to fixed, scarred sinus tracts.

Modification of drivers carries unusual weight in HS. Smoking cessation is the single most impactful lifestyle change a patient can make and is associated with meaningful reductions in flare frequency. Weight management, where applicable, reduces friction, hormonal load, and systemic inflammation, and can substantially improve disease activity. Friction reduction through loose, breathable clothing, gentle hair removal alternatives to shaving (such as laser hair reduction), and avoidance of occlusive products in affected areas all contribute. Antibacterial cleansing routines using gentle, fragrance-free, pH-balanced washes help manage bacterial burden without further compromising the skin barrier.

Equally important is recognition of HS as a systemic disorder requiring coordinated care. Screening and management of associated conditions — metabolic syndrome, diabetes, inflammatory bowel disease, mood disorders — should be integrated into the long-term care plan. Mental health support is not adjunctive but essential, given the documented psychological burden of the disease. Patient education on the chronic, relapsing nature of HS, the importance of adherence even during quiescent periods, and the availability of modern targeted therapies helps replace the cycle of shame and delayed care that has historically defined this condition.

With early diagnosis, evidence-based treatment, and a comprehensive long-term plan, HS is a manageable condition. Meaningful, sustained improvement in pain, drainage, scarring, and quality of life is an achievable outcome for the vast majority of patients.

​

​Products

​